← Back to Clinical Trials
Recruiting NCT07219992

NCT07219992 Parent-Based Treatment for Adolescent Anxiety

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07219992
Status Recruiting
Phase
Sponsor Yale University
Condition Anxiety Disorder of Adolescence
Study Type INTERVENTIONAL
Enrollment 108 participants
Start Date 2025-11-01
Primary Completion 2028-11

Trial Parameters

Condition Anxiety Disorder of Adolescence
Sponsor Yale University
Study Type INTERVENTIONAL
Phase N/A
Enrollment 108
Sex ALL
Min Age 14 Years
Max Age 17 Years
Start Date 2025-11-01
Completion 2028-11
Interventions
Supportive Parenting for Anxious Childhood Emotions (SPACE)Parent Educational Support (PES)

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

This study aims to test the efficacy of a parent-only approach to treating anxiety disorders in adolescents: SPACE (Supportive Parenting for Anxious Childhood Emotions). The comparator is another parent-based approach, PES (Parent Education and Support). The study design is a randomized controlled trial with 2 treatment arms and 3 assessment points (pre, post, and follow-up) using questionnaire data and clinical interviews.

Eligibility Criteria

Inclusion Criteria: * Meet criteria for a primary DSM-5 AD, including separation anxiety disorder, social anxiety disorder, generalized anxiety disorder, specific phobia, panic disorder, and agoraphobia (determined by the ADIS-C/P). * Cease all other psychosocial treatment, upon consultation with the project staff and service provider. * Not currently use any psychotropic medication, other than a stable dose (i.e., same dose for a minimum of 6 months prior to enrollment; no changes during course of the study) of a stimulant medication or selective serotonin reuptake inhibitor (SSRI). * Have an eligible and willing participating parent (see parent exclusions below). Exclusion Criteria: Adolescent: * Meet criteria for any DSM-5 disorder more impairing than the most impairing AD (determined by the ADIS-C/P). * Have any of the following disorders: autism spectrum disorder; intellectual disability; neurocognitive disorders; bipolar disorder; schizophrenia and other psychotic disorders; and

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology